AKTX

Akari Therapeutics Plc ADR

Apr 06 • 01:55PM ET

3.40

-1.07 -23.94 %

Healthcare • Biotechnology • USA • NASD

Today, 8:50 AMAkari Therapeutics announces strategic development and manufacturing partnership with WuXi XDC to support AKTX-101 IND by late 2026

Peers: REGN ALNY NBIX ARGX ADAP FATE CLLS TGTX MCRB VCNX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-19.27	Insider Own	28.24%	Shs Outstand	45.27M	Perf Week	-32.70%
Market Cap	153.92M	Forward P/E	-	EPS next Y	-5.60	Insider Trans	0.00%	Shs Float	32.48M	Perf Month	-65.53%
Enterprise Value	149.41M	PEG	-	EPS next Q	-1.80	Inst Own	0.00%	Short Float	0.01%	Perf Quarter	-70.69%
Income	-17.29M	P/S	-	EPS this Y	87.59%	Inst Trans	-	Short Ratio	0.43	Perf Half Y	-90.90%
Sales	0.00M	P/B	5.43	EPS next Y	20.00%	ROA	-35.05%	Short Interest	0.00M	Perf YTD	-70.59%
Book/sh	0.63	P/C	29.26	EPS next 5Y	52.62%	ROE	-68.39%	52W High	63.20 -94.62%	Perf Year	-92.38%
Cash/sh	0.12	P/FCF	-	EPS past 3/5Y	- -	ROIC	-61.03%	52W Low	4.16 -18.17%	Perf 3Y	-97.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	22.48% 15.70%	Perf 5Y	-99.84%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	13.85%	Oper. Margin	-	ATR (14)	1.03	Perf 10Y	-99.98%
Dividend Ex-Date	-	Quick Ratio	0.44	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	20.70	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.44	EPS Q/Q	-	SMA20	-49.42%	Beta	0.60	Target Price	35.67
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-60.25%	Rel Volume	41.21	Prev Close	4.47
Employees	6	LT Debt/Eq	0.00	Earnings	Dec 05	SMA200	-86.20%	Avg Volume	9.80K	Price	3.40
IPO	May 07, 2013	Option/Short	No / Yes	EPS/Sales Surpr.	-150.00% -	Trades		Volume	281,817	Change	-23.94%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Initiated	Ladenburg Thalmann	Buy	$1
Jul-18-25	Initiated	Maxim Group	Buy	$5
Jan-04-19	Upgrade	B. Riley FBR	Neutral → Buy	$2.50 → $3
Feb-08-18	Initiated	B. Riley FBR, Inc.	Neutral	$3
Sep-22-17	Upgrade	William Blair	Mkt Perform → Outperform
May-31-17	Upgrade	Chardan Capital Markets	Sell → Neutral	$6
Apr-17-17	Reiterated	Chardan Capital Markets	Sell	$6.50 → $5
Jul-11-16	Initiated	Chardan Capital Markets	Sell	$5

Today 08:45AM	Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing (GlobeNewswire) -23.94%
Mar-18-26 08:05AM	Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 (GlobeNewswire) -24.72%
Mar-17-26 04:30PM	Akari Therapeutics Announces ADS Ratio Change (GlobeNewswire)
Mar-13-26 09:15AM	Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala (GlobeNewswire) -10.71%
Feb-26-26 09:10AM	Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board (GlobeNewswire)
08:50AM	Loading…
Feb-23-26 08:50AM	Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board (GlobeNewswire)
Feb-18-26 09:05AM	Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference (GlobeNewswire)
Feb-11-26 08:45AM	Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing the Company's Expanded ADC Pipeline (GlobeNewswire)
Feb-05-26 09:15AM	Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial (GlobeNewswire)
Jan-26-26 08:45AM	Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors (GlobeNewswire)
Jan-17-26 07:00AM	MarketBeat Week in Review - 01/12 - 01/16 (MarketBeat)
Jan-09-26 09:00AM	Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 (GlobeNewswire)
Jan-08-26 09:15AM	Akari Therapeutics to Present at the 2026 Biotech Showcase (GlobeNewswire)
Dec-30-25 09:15AM	Akari Therapeutics Issues 2025 End of Year Letter to Shareholders (GlobeNewswire)
Dec-23-25 08:30AM	Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial (GlobeNewswire) -7.08%
08:30AM	Loading…
Dec-18-25 08:30AM	Akari Therapeutics Releases Virtual Investor "What This Means" Segment (GlobeNewswire)
Dec-16-25 09:29AM	Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market (GlobeNewswire) -38.30%
Dec-09-25 08:40AM	Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer (GlobeNewswire)
Dec-04-25 09:00AM	Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment (GlobeNewswire)
Nov-25-25 09:00AM	Akari Therapeutics Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Nov-18-25 08:35AM	Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer (GlobeNewswire) +12.04%
Nov-10-25 08:30AM	Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors (GlobeNewswire)
Nov-04-25 09:25AM	Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available (GlobeNewswire) +13.10%
Oct-30-25 08:35AM	Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP (GlobeNewswire)
Oct-22-25 09:05AM	Akari Therapeutics Announces Launch of CEO Corner Platform (GlobeNewswire)
Oct-15-25 08:30AM	Akari Therapeutics Announces $2.5 Million Registered Direct Offering (GlobeNewswire) -16.34%
Oct-10-25 08:50AM	Akari Therapeutics files two new patents with USPTO (TipRanks) -8.82%
Oct-09-25 08:45AM	Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1 (GlobeNewswire)
Oct-03-25 09:30AM	Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting (GlobeNewswire)
Sep-24-25 08:45AM	Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1 (GlobeNewswire) +45.96%
08:45AM	Loading…
Sep-17-25 08:45AM	Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer (GlobeNewswire) +5.11%
Sep-05-25 06:45AM	Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +12.15%
Sep-03-25 08:30AM	Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire) -6.42%
Aug-14-25 09:15AM	Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (GlobeNewswire)
Jul-29-25 09:15AM	Akari Therapeutics Releases Virtual Investor "What This Means" Segment (GlobeNewswire)
Jul-23-25 08:55AM	Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers (GlobeNewswire)
Jul-22-25 08:45AM	Akari Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jun-25-25 09:00AM	Akari Therapeutics Releases Virtual Investor "What This Means" Segment Highlighting its Recently Granted India Patent (GlobeNewswire)
Jun-18-25 08:50AM	Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India (GlobeNewswire)
May-29-25 09:15AM	Akari Therapeutics Releases "Meet the Team" Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development - Oncology (GlobeNewswire)
May-22-25 09:00AM	Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (GlobeNewswire)
May-19-25 08:00AM	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair (GlobeNewswire)
May-15-25 08:05AM	Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-25 08:45AM	Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology (GlobeNewswire)
Apr-22-25 09:05AM	Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala (GlobeNewswire) +6.25%
Apr-16-25 08:00AM	Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -8.24%
Mar-20-25 08:44AM	Akari Therapeutics appoints Abizer Gaslightwala as CEO (SeekingAlpha) +20.00%
08:35AM	Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer (GlobeNewswire)
Mar-03-25 09:00AM	Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules (GlobeNewswire) +7.70%
Feb-19-25 09:00AM	Akari Therapeutics Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire) +5.30%
Feb-03-25 08:00AM	Akari Therapeutics Joins Webull Corporate Connect Service Platform (GlobeNewswire) +9.17%
Dec-18-24 08:51AM	Akari Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
Dec-16-24 09:05AM	Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer (GlobeNewswire)
Nov-19-24 08:00AM	Akari Therapeutics Regains Full Nasdaq Compliance (GlobeNewswire) -31.44%
Nov-14-24 04:15PM	Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio (GlobeNewswire) -6.73%
Nov-08-24 08:00AM	Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger (GlobeNewswire)
Oct-15-24 08:00AM	Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger (GlobeNewswire)
Sep-17-24 08:00AM	Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics (GlobeNewswire)
Aug-19-24 04:15PM	Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) +5.42%
08:00AM	Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy (GlobeNewswire)
Jun-05-24 08:00AM	Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders (GlobeNewswire) +9.88%
Jun-04-24 08:00AM	Akari Therapeutics Secures $7.6 Million in Upsized Financing Round (GlobeNewswire) +14.20%
May-16-24 08:00AM	Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
May-01-24 08:01AM	Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics (GlobeNewswire) +10.39%
08:00AM	Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity (GlobeNewswire)
Apr-15-24 08:00AM	Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 (GlobeNewswire)
Apr-01-24 06:30AM	Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights (GlobeNewswire) -19.03%
Mar-08-24 04:38PM	Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm (GlobeNewswire)
Mar-05-24 08:00AM	Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit (GlobeNewswire)
Jan-02-24 08:00AM	Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing (GlobeNewswire) -7.16%
Dec-14-23 08:00AM	Akari Therapeutics to Present at Biotech Showcase 2024 (GlobeNewswire) +5.84%
Dec-01-23 08:00AM	Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors (GlobeNewswire) +9.49%
Nov-16-23 08:00AM	Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
Nov-06-23 08:00AM	Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
Oct-04-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now (GlobeNewswire) -5.21%
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire) +6.30%
Sep-29-23 08:00AM	Akari Therapeutics Reports First Half 2023 Financial Results and Highlights (GlobeNewswire)
Sep-27-23 08:00AM	Akari Therapeutics to Present at Emerging Growth Conference (GlobeNewswire)
Sep-21-23 08:00AM	Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit (GlobeNewswire)
Sep-19-23 08:00AM	Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs (GlobeNewswire)
Sep-05-23 08:00AM	Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.59%
Aug-21-23 02:01PM	British pharma opens U.S. headquarters in Boston (American City Business Journals)
Aug-18-23 08:00AM	Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials (GlobeNewswire) +10.00%
Aug-15-23 08:00AM	Akari Therapeutics, Plc Announces ADS Ratio Change (GlobeNewswire) -21.20%
Aug-02-23 08:00AM	Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs (GlobeNewswire)
Aug-01-23 07:30AM	Here's Why Akari Therapeutics (NASDAQ:AKTX) Must Use Its Cash Wisely (Simply Wall St.) +7.13%
Jul-27-23 08:00AM	Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation (GlobeNewswire) +7.94%
Jul-19-23 08:00AM	Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer (GlobeNewswire)
Jul-13-23 08:00AM	Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA (GlobeNewswire) +6.15%
Jul-11-23 08:00AM	Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy (GlobeNewswire)
Jul-06-23 08:00AM	Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation (GlobeNewswire)
Jul-05-23 08:00AM	Akari Therapeutics Appoints Industry Veteran Wael Hashad to Board of Directors (GlobeNewswire)
May-16-23 04:05PM	Aspira Womens Health Names Torsten Hombeck as Chief Financial Officer (GlobeNewswire) +12.28%
08:00AM	Akari Therapeutics to Participate in A.G.P.s Virtual Healthcare Conference (GlobeNewswire)
May-01-23 08:00AM	Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights (GlobeNewswire)
Apr-25-23 04:15PM	Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement (GlobeNewswire) +6.31%
Apr-19-23 02:01PM	Insiders rewarded with a US$607k addition on top of their US$1.3m purchase as Akari Therapeutics, Plc (NASDAQ:AKTX) hits US$22m (Simply Wall St.)
Apr-14-23 08:00AM	Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs (GlobeNewswire) +5.26%
Apr-11-23 08:00AM	Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology (GlobeNewswire)

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gaslightwala Abizer	CEO	Aug 21 '25	Buy	0.94	10,000	9,400	287,574	Aug 29 04:55 PM
Gaslightwala Abizer	CEO	Aug 22 '25	Buy	0.93	8,000	7,440	295,574	Aug 29 04:55 PM
Gaslightwala Abizer	CEO	Aug 25 '25	Buy	0.90	3,000	2,700	298,574	Aug 29 04:55 PM
Gaslightwala Abizer	President & CEO	Jun 24 '25	Buy	1.16	5,203	6,035	277,574	Jun 25 04:30 PM
Gaslightwala Abizer	President & CEO	Jun 23 '25	Buy	1.15	943	1,084	272,371	Jun 25 04:30 PM
Gaslightwala Abizer	President & CEO	Jun 20 '25	Buy	1.20	10,000	12,000	271,428	Jun 24 04:30 PM
Gaslightwala Abizer	President & CEO	Jun 17 '25	Buy	1.20	15,000	18,000	261,428	Jun 20 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKTX

Akari Therapeutics Plc ADR

Upgrade your Finviz experience